• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Mid-Cap Monday: ETF Fund Flows

    3/28/23 3:53:01 PM ET
    $LLY
    $QQQM
    $XOM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Integrated oil Companies
    Energy
    Get the next $LLY alert in real time by email

    The markets saw some green Monday after First Citizens Bank & Trust Co (NASDAQ:FCNCO) agreed to buy most of Silicon Valley Bank.

    The S&P 500 was up 0.29%, the Dow Jones Industrial Average gained 0.7%, while the NASDAQ Composite dropped 0.49% on the day.

    ETF Fund Flows

    We performed a screening of mid-cap ETFs - defined as having Assets Under Management (AUM) between $2 and $10 billion - to determine what funds gained and lost the most net assets over the last week, according to data from etfdb.com. Only non-leveraged funds were considered. 

    Winner

    Invesco NASDAQ 100 ETF (NASDAQ:QQQM)

    As of monday, QQQM added $530.81 million in net assets over the course of the last week, bringing its total AUM to just shy of $8.46 billion.

    The fund invests at least 90% of its assets in the securities that make up the NASDAQ 100 index. The NASDAQ 100 is made up of 101 securities issued by the largest non-financial companies listed on the NASDAQ.

    QQQM is very closely related to its big brother, QQQ, one of the largest and oldest ETFs in existence. QQQM has lower management fees and is a fraction of the price of QQQ, making it the preferred choice for many with less capital.

    QQQM is up 16.97% YTD.

    Loser

    iShares MSCI USA Momentum Factor ETF (BATS:MTUM)

    As of monday, MTUM lost $1.33 billion in net assets on the week. It’s total AUM now sits $9.55 billion.

    MTUM tracks an index of large-cap US stocks that show positive price momentum. The fund is diversified across sectors.

    It’s largest holdings are Eli Lilly and Company (NYSE:LLY) and Exxon Mobil Corporation (NYSE:XOM), which combined make up over 10% of the funds holdings.

    YTD, MTUM is down 7.11%.

    Get the next $LLY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LLY
    $QQQM
    $XOM

    CompanyDatePrice TargetRatingAnalyst
    Exxon Mobil Corporation
    $XOM
    4/21/2026Outperform → Peer Perform
    Wolfe Research
    Exxon Mobil Corporation
    $XOM
    4/17/2026$165.00Underperform → Neutral
    BNP Paribas Exane
    Exxon Mobil Corporation
    $XOM
    4/10/2026$175.00 → $172.00Buy
    TD Cowen
    Eli Lilly and Company
    $LLY
    3/17/2026$850.00Hold → Reduce
    HSBC Securities
    Eli Lilly and Company
    $LLY
    2/25/2026$1250.00Outperform
    RBC Capital Mkts
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    Exxon Mobil Corporation
    $XOM
    2/3/2026$125.00Neutral → Underperform
    BNP Paribas Exane
    Exxon Mobil Corporation
    $XOM
    2/3/2026$135.00 → $145.00Buy
    TD Cowen
    More analyst ratings

    $LLY
    $QQQM
    $XOM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

    Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi

    4/23/26 6:15:00 AM ET
    $LGVN
    $LLY
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies

    Kelonia's lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for relapsed/refractory multiple myeloma with clinical data recently highlighted in the 2025 ASH Annual Meeting plenary sessionAcquisition expands Lilly's genetic medicine capabilities with a novel in vivo gene delivery and integration technology that has potential for broad applicabilityINDIANAPOLIS and BOSTON, Mass., April 20, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Kelonia Therapeutics, Inc. ("Kelonia"), a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced a definitive agreement for Lilly to acquire Kelonia.Kelonia ha

    4/20/26 9:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly confirms date and conference call for first-quarter 2026 financial results announcement

    INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its first-quarter 2026 financial results on April 30, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.  The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  About LillyLilly is a medicine company turning science into heali

    4/16/26 10:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    $QQQM
    $XOM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Pres., Lilly Oncology Van Naarden Jacob bought $647,360 worth of shares (1,000 units at $647.36), increasing direct ownership by 5% to 20,562 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/13/25 4:15:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    $QQQM
    $XOM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 5, 2023 - FDA Roundup: December 5, 2023

    For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

    12/5/23 5:00:21 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    $QQQM
    $XOM
    SEC Filings

    View All

    SEC Form DEFA14A filed by Exxon Mobil Corporation

    DEFA14A - EXXON MOBIL CORP (0000034088) (Filer)

    4/9/26 10:42:14 AM ET
    $XOM
    Integrated oil Companies
    Energy

    SEC Form DEFA14A filed by Exxon Mobil Corporation

    DEFA14A - EXXON MOBIL CORP (0000034088) (Filer)

    4/8/26 4:13:36 PM ET
    $XOM
    Integrated oil Companies
    Energy

    SEC Form DEFA14A filed by Exxon Mobil Corporation

    DEFA14A - EXXON MOBIL CORP (0000034088) (Filer)

    4/8/26 4:10:10 PM ET
    $XOM
    Integrated oil Companies
    Energy

    $LLY
    $QQQM
    $XOM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sulzberger Gabrielle

    4 - ELI LILLY & Co (0000059478) (Issuer)

    4/21/26 4:20:53 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Luciano Juan R

    4 - ELI LILLY & Co (0000059478) (Issuer)

    4/21/26 4:18:58 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Fyrwald J Erik

    4 - ELI LILLY & Co (0000059478) (Issuer)

    4/21/26 4:16:39 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    $QQQM
    $XOM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Exxon Mobil downgraded by Wolfe Research

    Wolfe Research downgraded Exxon Mobil from Outperform to Peer Perform

    4/21/26 7:30:00 AM ET
    $XOM
    Integrated oil Companies
    Energy

    Exxon Mobil upgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane upgraded Exxon Mobil from Underperform to Neutral and set a new price target of $165.00

    4/17/26 8:05:13 AM ET
    $XOM
    Integrated oil Companies
    Energy

    TD Cowen reiterated coverage on Exxon Mobil with a new price target

    TD Cowen reiterated coverage of Exxon Mobil with a rating of Buy and set a new price target of $172.00 from $175.00 previously

    4/10/26 8:11:29 AM ET
    $XOM
    Integrated oil Companies
    Energy

    $LLY
    $QQQM
    $XOM
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Exxon Mobil Corporation on Jun 20

    Director Dreyfus Maria S. bought $2,000,386 worth of shares (18,310 units at $109.25), increasing direct ownership by 105% to 35,757 units (SEC Form 4) on June 20, 2024. This substantial insider purchase is a significant development for Exxon Mobil Corporation. As we delve into the recent insider activity at Exxon Mobil, we notice a few interesting patterns. Prior to Dreyfus Maria S.'s purchase, we observed that on January 4, 2024, Ubben Jeffrey W. granted 2,500 shares, which could signal confidence in the company. On the same day, Powell Dina H. claimed no ownership of stock but was granted 8,000 shares, indicating a new ownership stake. These events suggest a mix of adjustments in holding

    6/20/24 1:39:11 PM ET
    $XOM
    Integrated oil Companies
    Energy

    $LLY
    $QQQM
    $XOM
    Financials

    Live finance-specific insights

    View All

    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

    Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi

    4/23/26 6:15:00 AM ET
    $LGVN
    $LLY
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly confirms date and conference call for first-quarter 2026 financial results announcement

    INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its first-quarter 2026 financial results on April 30, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.  The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  About LillyLilly is a medicine company turning science into heali

    4/16/26 10:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ExxonMobil to Release First Quarter 2026 Financial Results

    Exxon Mobil Corporation (NYSE:XOM) will release its first quarter 2026 financial results on Friday, May 1, 2026. The company will issue a press release via Business Wire that will be available at 5:30 a.m. CT at investor.exxonmobil.com. Darren Woods, Chairman and Chief Executive Officer; Neil Hansen, Senior Vice President and Chief Financial Officer; and Jim Chapman, Vice President, Treasurer and Investor Relations, will review the results during a live conference call at 8:30 a.m. CT. The presentation will be accessible via webcast or by calling (800) 918-2066 (Toll-free) or (646) 307-1342 (Local). Please reference passcode 2207273 to join the call. An archived replay of the call and a c

    4/16/26 10:00:00 AM ET
    $XOM
    Integrated oil Companies
    Energy

    $LLY
    $QQQM
    $XOM
    Leadership Updates

    Live Leadership Updates

    View All

    Energy Security in a Shifting World: Why New Supply Frontiers Matter

    NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- NetworkNewsWire Editorial Coverage: Rising geopolitical tensions and renewed disruptions to global shipping lanes, particularly around the Strait of Hormuz, are once again underscoring a hard truth for policymakers: Energy security remains deeply fragile. The United States and Europe, despite years of diversification efforts, continue to face exposure to supply shocks that can ripple across economies, industries and households. Against this backdrop, companies working to unlock new, politically stable energy resources are drawing increased attention. One such company is Greenland Energy Company (NASDAQ:GLND) (profile), which is advancing explora

    4/8/26 8:30:00 AM ET
    $BP
    $CVX
    $GLND
    Integrated oil Companies
    Energy
    Oil & Gas Production

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

    INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D., will join Lilly as executive vice president and president, Lilly Neuroscience, and will serve on the Executive Committee. Ho brings more than 20 years of biopharmaceutical experience leading therapeutic development across neurology, rare diseases, immunology, and other areas. Most recently, she served as chief medical officer an

    11/6/25 4:05:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    $QQQM
    $XOM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    10/23/24 5:17:34 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    2/13/24 5:04:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Exxon Mobil Corporation (Amendment)

    SC 13G/A - EXXON MOBIL CORP (0000034088) (Subject)

    2/13/24 4:55:49 PM ET
    $XOM
    Integrated oil Companies
    Energy